Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787147 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HPGDGAAKMT2AMAPT | |
| SCHEMBL10787691 | 0.76 | RAB9A (0.55) | ALDH1A1NPC1RAB9AHPGDGAA | |
| SCHEMBL8944417 | 0.75 | HPGD (0.62) | ALDH1A1NPC1RAB9AHPGDGAA | |
| SCHEMBL3372005 | 0.73 | ALDH1A1 (0.57) | ALDH1A1HPGDGAAKMT2AMAPT | |
| SCHEMBL2739945 | 0.72 | ALDH1A1 (0.56) | ALDH1A1HPGDGAAKMT2AMAPT | |
| SCHEMBL10785269 | 0.70 | GAA (0.70) | ALDH1A1NPC1RAB9AHPGDGAA | |
| SCHEMBL5842593 | 0.70 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9AHPGDGAA | |
| SCHEMBL28803519 | 0.70 | CHRM2 (0.60) | ALDH1A1HPGDGAAMEN1KMT2A | |
| SCHEMBL23097564 | 0.69 | FERMT2 (0.55) | ALDH1A1HPGDGAAKMT2AMAPT | |
| SCHEMBL2434485 | 0.69 | ALDH1A1 (0.57) | ALDH1A1HPGDGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006121588-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |